Navigation Links
Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
Date:3/7/2012

SAN DIEGO, March  7, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the following two investor conferences in March:

  • 24th Annual Roth Conference in Dana Point on March 14, 2012 at 12:30 p.m. ET/9:30 a.m. PT. Kurt Gustafson, Chief Financial Officer of Halozyme Therapeutics, will provide a corporate overview.
  • Barclays Capital 2012 Global Healthcare Conference in Miami on March 14, 2012 at 4:15 p.m. ET/1:15 p.m. PT. Gregory I. Frost, Ph.D., President and Chief Executive Officer of Halozyme Therapeutics, will provide a corporate overview.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentations will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and recordings will be made available for 90 days following the events. To access the live webcasts, please log on to Halozyme's website approximately fifteen minutes prior to the presentations to register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headqua
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
2. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
3. Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
4. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
5. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
6. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
7. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
8. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
9. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
10. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
11. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 According to ... "Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, ... - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - ... 2013 - 2019," the global electrodes market for medical ... and is estimated to reach a market worth USD ...
(Date:7/31/2014)... Senomyx , Inc. (NASDAQ: ... taste science technologies to discover, develop, and commercialize ... ingredient supply industries, today reported financial results for ... second quarter with $33.6 million in cash and ... past quarter Senomyx achieved another important milestone with ...
(Date:7/31/2014)... Calif. (PRWEB) July 31, 2014 Held ... diagnosed patients with an overview of the disease and ... of drug side effects, as well as updates on ... grateful to Dr. Sandy Srinivas for organizing this educational ... of kidney cancer. “Sandy and her colleagues have put ...
(Date:7/31/2014)... Canada (PRWEB) July 31, 2014 ... some of the first transcriptome-wide analyses appearing around ... standard assay for RNA measurement. In the last ... throughput, more specific, work with smaller input amounts, ... tissues (eg, blood samples). On the bioinformatics side, ...
Breaking Biology Technology:Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2
... agents is time-consuming and expensive. Pharmaceutical companies may have ... bind a target molecule before they hit upon a ... Munich led by Professor Dieter Braun, a member of ... a partner in NanoTemper (an LMU spin-off), have now ...
... New ... ... 2010 -- Model N , Inc., the leader in Revenue Management solutions, today ... Model N Revenue Management Suite by allowing business users to rapidly develop contract documents ...
... ... ... ... ...
Cached Biology Technology:A hot road to new drugs 2Model N Extends its Industry-Leading Contract Management Offerings with Contract Authoring Capabilities 2Model N Extends its Industry-Leading Contract Management Offerings with Contract Authoring Capabilities 3Model N Extends its Industry-Leading Contract Management Offerings with Contract Authoring Capabilities 4Model N Extends its Industry-Leading Contract Management Offerings with Contract Authoring Capabilities 5Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism 2Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism 3Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism 4Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism 5Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism 6
(Date:7/31/2014)... week that the U.S. surgeon general issued a 101-page ... Montana State University published a paper breaking new ground ... cell responds when exposed to ultraviolet (UV) light. ... by the UV rays found in sunlight. This damage ... eye diseases. , "Our paper advances foundational knowledge ...
(Date:7/31/2014)... Most people are familiar with Hibiscus flowers- they ... where they are commonly planted in the landscape. ... - are endangered species. , Only a relatively ... aware of an equally beautiful and intriguing related ... literally "brother of Hibiscus". , Brother of Hibiscus ...
(Date:7/31/2014)... , July 31, 2014 ... unique and innovative smart technologies; companies turn towards digital ... EBAY ), Amazon.com Inc. (NASDAQ: AMZN ... Inc. (NASDAQ: GOOG ) and Microsoft Corporation ... company focused on the growing m-commerce market, announces a ...
Breaking Biology News(10 mins):New paper describes how DNA avoids damage from UV light 2New paper describes how DNA avoids damage from UV light 3Brother of Hibiscus is found alive and well on Maui 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 3Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 4Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 5Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 6
... cancer have remained largely unchanged over the past 60 years, ... disease with a very different theory of its origin that ... a billion years ago. In this month,s ... "physics of cancer", Paul Davies, principal investigator at Arizona State ...
... In the world, there are a lot of small ... at least convert to something useful, according to University ... dioxide, the greenhouse gas most responsible for far-reaching effects ... that can be transformed into the valuable agricultural fertilizer ...
... Ann Liebert, Inc., publishers announces the launch of ... innovative, peer-reviewed journal on this rapidly growing disruptive technology. ... 2013, and quarterly thereafter in 2014. Editor-in-Chief Hod Lipson, ... Lab at the Sibley School of Mechanical and Aerospace ...
Cached Biology News:Cancer is a result of a default cellular 'safe mode,' physicist proposes 2Diamond catalyst shows promise in breaching age-old barrier 2
... for the use of small interfering RNA ... the RNA interference (RNAi) pathway have generated ... biology fields. siRNA for experimental use can ... enzymatically, and then transfected into the target ...
... potential applications for the use of small ... expression via the RNA interference,(RNAi) pathway have ... molecular biology fields. siRNA for experimental use ... enzymatically, and then transfected into the target ...
... The HybArray 12™ is an automated hybridization ... The system automates both the hybridization and ... glass slides. A single instrument can process ... in pairs and has multi-protocol software, enabling ...
... is commonly used as a fusion partner ... The GSTTag sequence has been reported to ... the solubility of its fusion partners. When ... GSTTag fusion proteins can be purified with ...
Biology Products: